Is STTK or BHVN more profitable?

Shattuck Labs' return on equity of -60.73% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Biohaven N/A -866.46% -137.99%

Is STTK or PVLA more profitable?

Palvella Therapeutics' return on equity of -56.87% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Palvella Therapeutics N/A -56.87% -42.50%

Is STTK or RAPP more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Rapport Therapeutics N/A -24.78% -23.44%

Shattuck Labs (STTK) Competitors

$7.50 +0.21 (+2.88%)

As of 12:04 PM Eastern

Compare

STTK vs. BHVN, HRMY, PVLA, ADMA, and RAPP

Should you buy Shattuck Labs stock or one of its competitors? MarketBeat compares Shattuck Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Shattuck Labs include Biohaven (BHVN), Harmony Biosciences (HRMY), Palvella Therapeutics (PVLA), ADMA Biologics (ADMA), and Rapport Therapeutics (RAPP).

How does Shattuck Labs compare to Biohaven?

Shattuck Labs (NASDAQ:STTK) and Biohaven (NYSE:BHVN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Shattuck Labs has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Shattuck Labs has higher revenue and earnings than Biohaven. Shattuck Labs is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	575.10	-$48.81M	-$0.63	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 13.8% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Biohaven had 7 more articles in the media than Shattuck Labs. MarketBeat recorded 7 mentions for Biohaven and 0 mentions for Shattuck Labs. Biohaven's average media sentiment score of 0.84 beat Shattuck Labs' score of 0.00 indicating that Biohaven is being referred to more favorably in the news media.

Company	Overall Sentiment
Shattuck Labs	Neutral
Biohaven	Positive

Shattuck Labs presently has a consensus price target of $12.63, suggesting a potential upside of 68.33%. Biohaven has a consensus price target of $21.63, suggesting a potential upside of 59.89%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities research analysts plainly believe Shattuck Labs is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

Shattuck Labs' return on equity of -60.73% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Biohaven	N/A	-866.46%	-137.99%

Summary

Shattuck Labs and Biohaven tied by winning 7 of the 14 factors compared between the two stocks.

How does Shattuck Labs compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Shattuck Labs (NASDAQ:STTK) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Harmony Biosciences presently has a consensus target price of $42.63, suggesting a potential upside of 12.36%. Shattuck Labs has a consensus target price of $12.63, suggesting a potential upside of 68.33%. Given Shattuck Labs' stronger consensus rating and higher possible upside, analysts plainly believe Shattuck Labs is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Harmony Biosciences had 14 more articles in the media than Shattuck Labs. MarketBeat recorded 14 mentions for Harmony Biosciences and 0 mentions for Shattuck Labs. Harmony Biosciences' average media sentiment score of 0.99 beat Shattuck Labs' score of 0.00 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Harmony Biosciences	Positive
Shattuck Labs	Neutral

Harmony Biosciences has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.53	$158.69M	$2.48	15.30
Shattuck Labs	$1M	575.10	-$48.81M	-$0.63	N/A

Harmony Biosciences has a net margin of 16.20% compared to Shattuck Labs' net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Shattuck Labs	N/A	-60.73%	-55.75%

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Harmony Biosciences has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Summary

Harmony Biosciences beats Shattuck Labs on 12 of the 17 factors compared between the two stocks.

How does Shattuck Labs compare to Palvella Therapeutics?

Shattuck Labs (NASDAQ:STTK) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Palvella Therapeutics had 11 more articles in the media than Shattuck Labs. MarketBeat recorded 11 mentions for Palvella Therapeutics and 0 mentions for Shattuck Labs. Palvella Therapeutics' average media sentiment score of 1.03 beat Shattuck Labs' score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Shattuck Labs	Neutral
Palvella Therapeutics	Positive

Palvella Therapeutics' return on equity of -56.87% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Shattuck Labs has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market.

Shattuck Labs currently has a consensus target price of $12.63, indicating a potential upside of 68.33%. Palvella Therapeutics has a consensus target price of $207.36, indicating a potential upside of 37.15%. Given Shattuck Labs' higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Palvella Therapeutics has higher revenue and earnings than Shattuck Labs. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	575.10	-$48.81M	-$0.63	N/A
Palvella Therapeutics	$42.81M	50.64	-$41.72M	-$4.17	N/A

Summary

Palvella Therapeutics beats Shattuck Labs on 10 of the 16 factors compared between the two stocks.

How does Shattuck Labs compare to ADMA Biologics?

Shattuck Labs (NASDAQ:STTK) and ADMA Biologics (NASDAQ:ADMA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

ADMA Biologics has a net margin of 32.43% compared to Shattuck Labs' net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
ADMA Biologics	32.43%	39.98%	28.08%

Shattuck Labs presently has a consensus target price of $12.63, indicating a potential upside of 68.33%. ADMA Biologics has a consensus target price of $18.67, indicating a potential upside of 109.15%. Given ADMA Biologics' higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, ADMA Biologics had 39 more articles in the media than Shattuck Labs. MarketBeat recorded 39 mentions for ADMA Biologics and 0 mentions for Shattuck Labs. ADMA Biologics' average media sentiment score of 0.09 beat Shattuck Labs' score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Shattuck Labs	Neutral
ADMA Biologics	Neutral

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 3.9% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Shattuck Labs has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	575.10	-$48.81M	-$0.63	N/A
ADMA Biologics	$510.17M	4.05	$146.93M	$0.68	13.13

Summary

ADMA Biologics beats Shattuck Labs on 11 of the 16 factors compared between the two stocks.

How does Shattuck Labs compare to Rapport Therapeutics?

Shattuck Labs (NASDAQ:STTK) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Shattuck Labs has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

58.7% of Shattuck Labs shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Rapport Therapeutics had 5 more articles in the media than Shattuck Labs. MarketBeat recorded 5 mentions for Rapport Therapeutics and 0 mentions for Shattuck Labs. Rapport Therapeutics' average media sentiment score of 0.37 beat Shattuck Labs' score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Shattuck Labs	Neutral
Rapport Therapeutics	Neutral

Shattuck Labs currently has a consensus target price of $12.63, suggesting a potential upside of 68.33%. Rapport Therapeutics has a consensus target price of $57.86, suggesting a potential upside of 39.93%. Given Shattuck Labs' higher possible upside, research analysts clearly believe Shattuck Labs is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Rapport Therapeutics' return on equity of -24.78% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Shattuck Labs has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	575.10	-$48.81M	-$0.63	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Summary

Shattuck Labs and Rapport Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Shattuck Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STTK vs. The Competition

Export

Metric	Shattuck Labs	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$576.02M	$3.54B	$6.81B	$12.94B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-11.92	7.33	279.92	25.45
Price / Sales	575.10	1,273.99	647.84	115.11
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	5.77	17.12	11.11	6.33
Net Income	-$48.81M	-$12.52M	$3.48B	$347.60M
7 Day Performance	9.97%	1.99%	2.04%	2.78%
1 Month Performance	6.38%	-5.83%	-3.16%	-2.36%
1 Year Performance	909.83%	50.13%	63.65%	20.74%

Shattuck Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STTK Shattuck Labs	2.359 of 5 stars	$7.50 +2.9%	$12.63 +68.3%	+895.9%	$576.02M	$1M	N/A	100
BHVN Biohaven	3.6308 of 5 stars	$13.76 -5.2%	$21.63 +57.2%	-9.2%	$2.07B	N/A	N/A	239	Upcoming Earnings Gap Up
HRMY Harmony Biosciences	4.0473 of 5 stars	$35.77 -0.7%	$42.50 +18.8%	+3.5%	$2.07B	$899.11M	14.42	200	News Coverage Earnings Report
PVLA Palvella Therapeutics	3.6227 of 5 stars	$142.84 +0.8%	$199.53 +39.7%	+285.2%	$2.05B	N/A	N/A	N/A	Earnings Report Gap Up
ADMA ADMA Biologics	4.5877 of 5 stars	$8.79 +3.7%	$18.67 +112.4%	-54.8%	$2.04B	$510.17M	12.93	530	Trending News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STTK) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shattuck Labs (STTK) Competitors

STTK vs. BHVN, HRMY, PVLA, ADMA, and RAPP

How does Shattuck Labs compare to Biohaven?

Summary

How does Shattuck Labs compare to Harmony Biosciences?

Summary

How does Shattuck Labs compare to Palvella Therapeutics?

Summary

How does Shattuck Labs compare to ADMA Biologics?

Summary

How does Shattuck Labs compare to Rapport Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shattuck Labs (STTK) Competitors

STTK vs. BHVN, HRMY, PVLA, ADMA, and RAPP

How does Shattuck Labs compare to Biohaven?

Which has more risk & volatility, STTK or BHVN?

Which has better earnings and valuation, STTK or BHVN?

Do institutionals & insiders have more ownership in STTK or BHVN?

Does the media refer more to STTK or BHVN?

Do analysts rate STTK or BHVN?

Is STTK or BHVN more profitable?

Summary

How does Shattuck Labs compare to Harmony Biosciences?

Do analysts prefer HRMY or STTK?

Does the media favor HRMY or STTK?

Which has stronger earnings and valuation, HRMY or STTK?

Is HRMY or STTK more profitable?

Do insiders and institutionals hold more shares of HRMY or STTK?

Which has more volatility & risk, HRMY or STTK?

Summary

How does Shattuck Labs compare to Palvella Therapeutics?

Does the media favor STTK or PVLA?

Is STTK or PVLA more profitable?

Which has more volatility and risk, STTK or PVLA?

Do analysts rate STTK or PVLA?

Do institutionals and insiders believe in STTK or PVLA?

Which has higher earnings and valuation, STTK or PVLA?

Summary

How does Shattuck Labs compare to ADMA Biologics?

Is STTK or ADMA more profitable?

Do analysts recommend STTK or ADMA?

Does the media prefer STTK or ADMA?

Do institutionals & insiders hold more shares of STTK or ADMA?

Which has more volatility and risk, STTK or ADMA?

Which has higher valuation & earnings, STTK or ADMA?

Summary

How does Shattuck Labs compare to Rapport Therapeutics?

Which has more volatility & risk, STTK or RAPP?

Do institutionals and insiders have more ownership in STTK or RAPP?

Does the media favor STTK or RAPP?

Do analysts prefer STTK or RAPP?

Is STTK or RAPP more profitable?

Which has stronger earnings & valuation, STTK or RAPP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools